The price of HOOKIPA Pharma Inc. (NASDAQ:HOOK) shares last traded on Wall Street fell -0.01% to $1.00.
Based on available information, 8 analysts follow HOOKIPA Pharma Inc. (NASDAQ:HOOK). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $11.00 and a low of $0.50, we find $5.00. Given the previous closing price of $1.00, this indicates a potential upside of 400.0 percent. HOOK stock price is now 5.78% away from the 50-day moving average and -27.77% away from the 200-day moving average. The market capitalization of the company currently stands at $55.79M.
Among analysts, 1 rate the stock a hold while 6 rate it a buy. Brokers who have rated the stock have averaged $5.31 as their price target over the next twelve months.
With the price target maintained at $0.50, BofA Securities recently Downgraded its rating from Buy to Underperform for HOOKIPA Pharma Inc. (NASDAQ: HOOK)., while ‘Morgan Stanley’ rates the stock as ‘Equal-Weight’.
A total of 8.15% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in HOOK stock. A new stake in HOOKIPA Pharma Inc. shares was purchased by ACADIAN ASSET MANAGEMENT LLC during the first quarter worth $73,000. TWO SIGMA INVESTMENTS, LP invested $38,000 in shares of HOOK during the first quarter. In the first quarter, CHARLES SCHWAB INVESTMENT MANAGEMENT INC acquired a new stake in HOOKIPA Pharma Inc. valued at approximately $36,000. CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. acquired a new stake in HOOK for approximately $22,000. MAN GROUP PLC purchased a new stake in HOOK valued at around $10,000 in the second quarter. In total, there are 82 active investors with 62.90% ownership of the company’s stock.
A candlestick chart of HOOKIPA Pharma Inc. (NASDAQ: HOOK) showed a price of $1.0500 on Monday morning. During the past 12 months, HOOKIPA Pharma Inc. has had a low of $0.72 and a high of $3.05. As of last week, the company has a debt-to-equity ratio of 0.03, a current ratio of 5.00, and a quick ratio of 5.00. The fifty day moving average price for HOOK is $0.9453 and a two-hundred day moving average price translates $1.3843 for the stock.
The latest earnings results from HOOKIPA Pharma Inc. (NASDAQ: HOOK) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.23, beating analysts’ expectations of -$0.36 by 0.13. This compares to -$0.61 EPS in the same period last year. The company reported revenue of $2.23 million for the quarter, compared to $3.87 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -42.44 percent. For the current quarter, analysts expect HOOK to generate $2.91M in revenue.
HOOKIPA Pharma Inc.(HOOK) Company Profile
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company’s preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.